Tempest Therapeutics Receives Nasdaq Notice Over Minimum Bid Price Deficiency

• Tempest Therapeutics received a Nasdaq noncompliance notice November 4, 2026, following 30 consecutive business days with its common stock below $1.
• The notice has no immediate effect on its listing or business operations.
• Compliance requires a closing bid price of at least $1 for 10 consecutive business days before May 3, 2027, the 180-calendar-day deadline.
• An additional 180-day compliance period may be available subject to listing requirements and written commitment to a reverse stock split if necessary.
• Failure to qualify for an extension or regain compliance could trigger delisting, subject to appeal.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempest Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-116484), on November 06, 2026, and is solely responsible for the information contained therein.